Genus Pharmaceuticals
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Genus Pharmaceuticals
Deals Shaping The Medical Industry, February 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014-January 2015.
Recent Tech Transfer Deals, March 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.
Bronchitol Gets Final NICE OK, TOBI Podhaler Trumps Colobreathe
Pharmaxis’ Bronchitol became the first cystic fibrosis drug to get a NICE final approval, while Novartis’s TOBI Podhaler was selected ahead of Forest Lab’s Colobreathe for bacterial infection.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice